The job cuts come after sales of some of the drug giant’s lead products dwindled, including drugs made at the Cork plant.
Finbar Whyte, vice president of GSK, commented “As a company, we have to anticipate and respond to changing market situations. This proposal is regrettable, however it does represent the best strategic route for the Cork site and for GSK overall.”
He added, “We are committed to working closely with all employees to ensure that we are able to safeguard the future of GSK Cork and, most importantly, protect employment at the site wherever possible.”
Other pharmaceutical companies having announced job losses in Cork include Pfizer, Corden and Schering-Plough.